ea0021p404 | Thyroid | SFEBES2009
Muralidhara Koteshwara
, Joseph Debra
, Guzder Rustom
, Rudman Sarah
, McGowan Barbara
, Chowdhury Simon
, Carroll Paul
, Powrie Jake
Sunitinib, a tyrosine kinase inhibitor, inhibits VEGF-mediated tumour angiogenesis. Following NICE approval, it is increasingly used in the treatment of metastatic renal cell carcinoma.Hypothyroidism in sunitinib-treated individuals was first described in 2005. The aetiology remains uncertain and possibly reflects a destructive thyroiditis. Incidence rates of hypothyroidism from case series vary between 36 and 85%. We report a retrospective analysis of t...